The diagnostic performance of stool DNA testing for colorectal cancer a systematic review and meta-analysis

Medicine (United States)

Volumn 95, Issue 5, 2016, Pages

  Zhai, Rong Lin ^a   Xu, Fei ^a   Zhang, Pei ^a   Zhang, Wan Li ^a   Wang, Hui ^a   Wang, Ji Liang ^a   Cai, Kai Lin ^a   Long, Yue Ping ^a   Lu, Xiao Ming ^a   Tao, Kai Xiong ^a   Wang, Guo Bin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL CANCER; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FECES ANALYSIS; GENETIC SCREENING; HUMAN; META ANALYSIS; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; STOOL DNA TESTING; SYSTEMATIC REVIEW; CHEMISTRY; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; FECES; MASS SCREENING; PROCEDURES; TUMOR GENE;

COLORECTAL NEOPLASMS; DNA; FECES; GENES, NEOPLASM; HUMANS; MASS SCREENING; ROC CURVE;

EID: 84958778856     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002129     Document Type: Review

References (71)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Pfister DG, Benson AB 3rd, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med. 2004;350:2375-2382.
3. Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol. 2005;23:378-391.
4. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573.
5. Berger BM, Ahlquist DA. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates. Pathology. 2012;44:80-88.
6. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135:1079-1099.
7. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449-2460.
8. Muller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet. 2004;363:1283-1285.
9. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65-94.
10. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529-536.
11. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12: 1293-1316.
12. Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6:31.
13. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
14. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58: 882-893.
15. Abbaszadegan MR, Tavasoli A, Velayati A, et al. Stool-based DNA testing, a new noninvasive method for colorectal cancer screening, the first report from Iran. World J Gastroenterol. 2007;13:1528-1533.
16. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000;119: 1219-1227.
17. Ahlquist DA, Taylor WR, Mahoney DW, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol. 2012;10:272-277.
18. Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142:248-256.
19. Azuara D, Rodriguez-Moranta F, de Oca J, et al. Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin Colorectal Cancer. 2010;9:168-176.
20. Baek YH, Chang E, Kim YJ, et al. Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis Colon Rectum. 2009;52:1452-1459.
21. Bosch LJ, Oort FA, Neerincx M, et al. DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT. Cancer Prev Res (Phila). 2012;5:464-472.
22. Calistri D, Rengucci C, Bocchini R, et al. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol. 2003;1:377-383.
23. Calistri D, Rengucci C, Lattuneddu A, et al. Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stool. Neoplasia. 2004;6:536-540.
24. Calistri D, Rengucci C, Molinari C, et al. Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer. Cell Oncol. 2009;31:11-17.
25. Carmona FJ, Azuara D, Berenguer-Llergo A, et al. DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer. Cancer Prev Res (Phila). 2013;6:656-665.
26. Chang E, Park DI, Kim YJ, et al. Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: a preliminary report in Korean patients. Hepatogastroenterology. 2010;57:720-727.
27. Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005;97:1124-1132.
28. Cheng ZH. Stool SFRP2 methylation in the diagnosis of colorectal cancer. Shandong Yiyao Zazhi. 2007;47:10-12.
29. Fu L, Sheng JQ, Meng XM, et al. Stool Vimentin methylation in the diagnosis of colorectal cancer. Weichangbing Ji Ganzabingxue Zazhi. 2010;19:601-603.
30. Glockner SC, Dhir M, Yi JM, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 2009;69:4691-4699.
31. Guo Q, Song Y, Zhang H, et al. Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients. Med Oncol. 2013;30:695.
32. Hellebrekers DM, Lentjes MH, van den Bosch SM, et al. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res. 2009;15:3990-3997.
33. Huang ZH, Li LH, Yang F, et al. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol. 2007;13:950-954.
34. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351:2704-2714.
35. Itzkowitz S, Brand R, Jandorf L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. 2008;103:2862-2870.
36. Itzkowitz SH, Jandorf L, Brand R, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol. 2007;5:111-117.
37. Kalimutho M, Del Vecchio Blanco G, Cretella M, et al. A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection. Int J Colorectal Dis. 2011;26:583-592.
38. Kang YP, Cao FA, Chang WJ, et al. Gene methylation in stool for the screening of colorectal cancer and pre-malignant lesions. Zhonghua Wei Chang Wai Ke Za Zhi. 2011;14:52-56.
39. Kim MS, Louwagie J, Carvalho B, et al. Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. PLoS One. 2009;4:e6555.
40. Koga Y, Yasunaga M, Moriya Y, et al. Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis. Cancer Sci. 2008;99:1977-1983.
41. Koshiji M, Yonekura Y, Saito T, et al. Microsatellite analysis of fecal DNA for colorectal cancer detection. J Surg Oncol. 2002;80:34-40.
42. Kutzner N, Hoffmann I, Linke C, et al. Non-invasive detection of colorectal tumours by the combined application of molecular diagnosis and the faecal occult blood test. Cancer Lett. 2005;229:33-41.
43. Lenhard K, Bommer GT, Asutay S, et al. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol. 2005;3:142-149.
44. Leung WK, To KF, Man EP, et al. Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin Chem. 2004;50:2179-2182.
45. Leung WK, To KF, Man EP, et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol. 2007;102:1070-1076.
46. Li BS, Wang XY, Xu AG, et al. High-resolution melting assay (HRMA) is a simple and sensitive stool-based DNA test for the detection of mutations in colorectal neoplasms. Clin Colorectal Cancer. 2012;11:280-290.
47. Li M, Chen WD, Papadopoulos N, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol. 2009;27:858-863.
48. Ling ZA, Chen LS, He CG. Stool P16 methylation in the diagnosis of colorectal cancer. Jiezhichang Gangmen Waike. 2009;15:144-148.
49. Matsushita H, Matsumura Y, Moriya Y, et al. A new method for isolating colonocytes from naturally evacuated feces and its clinical application to colorectal cancer diagnosis. Gastroenterology. 2005;129:1918-1927.
50. Mayor R, Casadome L, Azuara D, et al. Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. Br J Cancer. 2009;100:1534-1539.
51. Melotte V, Lentjes MH, van den Bosch SM, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst. 2009;101:916-927.
52. Nagasaka T, Tanaka N, Cullings HM, et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst. 2009;101:1244-1258.
53. Nishikawa T, Maemura K, Hirata I, et al. A simple method of detecting K-ras point mutations in stool samples for colorectal cancer screening using one-step polymerase chain reaction/restriction fragment length polymorphism analysis. Clin Chim Acta. 2002;318:107-112.
54. Tagore KS, Lawson MJ, Yucaitis JA, et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer. 2003;3:47-53.
55. Tang D, Wang D, Li H. Combination analysis of hypermethylated SFRP1 and SFRP2 gene in fecal as a novel epigenetic biomarker panel for colorectal cancer screening. J Nanjing Medical University. 2008;22:96-101.
56. Tang D, Liu J, Wang DR, et al. Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. Clin Invest Med. 2011;34:E88-95.
57. Wan J, Zhang ZQ, You WD, et al. Detection of K-ras gene mutation in fecal samples from elderly large intestinal cancer patients and its diagnostic significance. World J Gastroenterol. 2004;10:743-746.
58. Wang DR, Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol. 2008;14:524-531.
59. Xu MH, Cai KY, Tu Y. Stool DNA methylation analysis in the early diagnosis of colorectal cancer. Linchang Xiaohuabing Zazhi. 2012;24:7-19.
60. Yehya AH, Yusoff NM, Khalid IA, et al. Pilot study of the sensitivity and specificity of the DNA integrity assay for stool-based detection of colorectal cancer in Malaysian patients. Asian Pac J Cancer Prev. 2012;13:1869-1872.
61. Zhang H, Zhu YQ, Wu YQ, et al. Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer. World J Gastroenterol. 2014;20:6329-6335.
62. Zhang H, Song YC, Dang CX. Detection of hypermethylated spastic paraplegia-20 in stool samples of patients with colorectal cancer. Int J Med Sci. 2013;10:230-234.
63. Zhang J, Yang S, Xie Y, et al. Detection of methylated tissue factor pathway inhibitor 2 and human long DNA in fecal samples of patients with colorectal cancer in China. Cancer Epidemiol. 2012;36:73-77.
64. Zhang JP, Wang J, Gui YL, et al. Stool DNA methylation in the diagnosis of colorectal cancer. Zhonghua Yixue Zazhi. 2011;95:2482-2484.
65. Zhang W, Bauer M, Croner RS, et al. DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis Colon Rectum. 2007;50:1618-1626.
66. Zou H, Harrington JJ, Klatt KK, et al. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2006;15:1115-1119.
67. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149:441-450.
68. Yang H, Xia BQ, Jiang B, et al. Diagnostic value of stool DNA testing for multiple markers of colorectal cancer and advanced adenoma: a meta-analysis. Can J Gastroenterol. 2013;27:467-475.
69. Zhang H, Qi J, Wu YQ, et al. Accuracy of early detection of colorectal tumours by stool methylation markers: a meta-analysis. World J Gastroenterol. 2014;20:14040-14050.
70. Luo YX, Chen DK, Song SX, et al. Aberrant methylation of genes in stool samples as diagnostic biomarkers for colorectal cancer or adenomas: a meta-analysis. Int J Clin Pract. 2011;65:1313-1320.
71. Skally M, Hanly P, Sharp L. Cost effectiveness of fecal DNA screening for colorectal cancer: a systematic review and quality appraisal of the literature. Appl Health Econ Health Policy. 2013;11: 181-192.